Drug Res (Stuttg) 2017; 67(01): 46-51
DOI: 10.1055/s-0042-118173
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers

S. K. Bedada
1   Drug Metabolism and Pharmacokinetics Division, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Telangana State, India
,
R. Appani
2   Department of Pharmaceutical Chemistry, Nethaji Institute of Pharmaceutical Sciences, Kakatiya University, Warangal, Telangana State, India
,
P. K. Boga
1   Drug Metabolism and Pharmacokinetics Division, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Telangana State, India
› Author Affiliations
Further Information

Publication History

received 27 August 2016

accepted 23 September 2016

Publication Date:
24 October 2016 (online)

Abstract

Carbamazepine (CBZ) is a widely used antiepileptic drug with narrow therapeutic window and it may be prone to drug interactions. The purpose of present study was to investigate the effect of PIP on metabolism and pharmacokinetics of CBZ in healthy volunteers. An open-label, 2 period, sequential study was conducted in 12 healthy volunteers. PIP 20 mg was administered once daily for 10 days during treatment phase. A single dose of CBZ 200 mg was administered during control and after treatment phases under fasting conditions. The blood samples were collected after CBZ dosing at predetermined time intervals and analyzed by LC-MS/MS method. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax), area under the curve (AUC) and half life (T1/2) of CBZ by 68.7, 47.9 and 43.2%, respectively as compared to control. On the other hand, elimination rate constant (Kel) and apparent oral clearance (CL/F) of CBZ were significantly decreased by 23.8 and 38.9%, respectively upon PIP treatment as compared to control. Furthermore, PIP treatment significantly decreased metabolic (CBZE/CBZ) ratios of Cmax and AUC, indicating the decreased formation of CBZ to CBZE. The results suggest that the altered CYP3A4 enzyme activity and pharmacokinetics of CBZ might be attributed to PIP mediated inhibition of CYP3A4 enzyme. Thus, there is a potential pharmacokinetic interaction present between PIP and CBZ. Accordingly, caution should be taken when PIP is used in combination with therapeutic drugs metabolized by CYP3A4 in addition to CBZ.

 
  • References

  • 1 Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24: 475-490
  • 2 Evans AM. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 2000; 22: 131-136
  • 3 Ioannides C. Drug-phytochemical interactions. Inflammopharmacology 2003; 11: 7-42
  • 4 Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr 2007; 47: 735-748
  • 5 Meghwal M, Goswami TK. Piper nigrum and piperine: an update. Phytother Res 2013; 27: 1121-1130
  • 6 Mishra A, Punia JK, Bladen C et al. Anticonvulsant mechanisms of piperine, a piperidine alkaloid. Channels (Austin) 2015; 9: 317-323
  • 7 Han HK. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opin Drug Metab Toxicol 2011; 7: 721-729
  • 8 Koul S, Koul JL, Taneja SC et al. Structure-activity relationship of piperine and its synthetic analogues for their inhibitory potentials of rat hepatic microsomal constitutive and inducible cytochrome P450 activities. Bioorg Med Chem 2000; 8: 251-268
  • 9 Atal CK, Dubey RK, Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 1985; 232: 258-262
  • 10 Bano G, Amla V, Raina RK et al. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med 1987; 53: 568-569
  • 11 Velpandian T, Jasuja R, Bhardwaj RK et al. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet 2001; 26: 241-247
  • 12 Pattanaik S, Hota D, Prabhakar S et al. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res 2006; 20: 683-686
  • 13 Rezaee MM, Kazemi S, Kazemi MT et al. The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism. Daru 2014; 22: 8
  • 14 Bano G, Raina RK, Zutshi U et al. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991; 41: 615-617
  • 15 Shahzadi A, Javed I, Aslam B et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci 2011; 24: 63-68
  • 16 So EL, Ruggles KH, Cascino GD et al. Seizure exacerbation and status epilepticus related to carbamazepine-10, 11-epoxide. Ann Neurol 1994; 35: 743-746
  • 17 Fong SY, Gao Q, Zuo Z. Interaction of carbamazepine with herbs, dietary supplements, and food: a systematic review. Evid Based Complement Alternat Med 2013; 2013: 898261
  • 18 Spina E, Arena D, Scordo MG et al. Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. Ther Drug Monit 1997; 19: 535-538
  • 19 Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers. Phytother Res 2015; 29: 701-706
  • 20 Pattanaik S, Hota D, Prabhakar S et al. Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients. Phytother Res 2009; 23: 1281-1286
  • 21 Van Rooyen GF, Badenhorst D, Swart KJ et al. Determination of carbamazepine and carbamazepine 10, 11-epoxide in human plasma by tandem liquid chromatography-mass spectrometry with electrospray ionisation. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 769: 1-7
  • 22 Bhardwaj RK, Glaeser H, Becquemont L et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 302: 645-650
  • 23 Garg SK, Kumar N, Bhargava VK et al. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther 1998; 64: 286-288
  • 24 Kato Y, Fujii T, Mizoguchi N et al. Potential interaction between ritonavir and carbamazepine. Pharmacotherapy 2000; 20: 851-854